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Abstract
Background The optimal dose of low molecular weight
heparin (LMWH) to prevent venous thromboembolism
(VTE) after bariatric surgery remains controversial. The aim
of this multicentre, open-label, pilot study was to evaluate the
efficacy and safety of two different doses of the LMWH
parnaparin administered to patients undergoing bariatric
surgery.
Methods Patients were randomised to receive 4,250 IU/day
(group A) or 6,400 IU/day (group B) of parnaparin s.c.
for 7–11 days. Bilateral colour Doppler ultrasound of the
lower limb was performed before surgery and at the end
of the treatment period. The primary efficacy outcome was
a composite of asymptomatic and symptomatic deep vein
thrombosis, symptomatic pulmonary embolism and death
from any cause during treatment. The primary safety
endpoint was major and clinically relevant non-major
bleeding.
Results A total of 258 patients underwent randomization; 8
subjects were excluded following the safety analysis. One
hundred thirty-one patients [106 females;mean age, 40.3 years
(standard deviation (SD) ±9.6); mean bodymass index (BMI),
44.6 kg/m2 (SD ±5.4)] were assigned to group A and 119
patients [93 females; mean age, 41.5 years (SD ±9.9); mean
BMI, 44.2 kg/m2 (SD ±5.4)] were assigned to group B.
The rate of the primary efficacy outcome was 1.5 % (two
cases; 95 % confidence interval (CI), 0.2–6.0 %) in group
A as compared with 0.8 % (one case; 95 % CI, 0.4–5.3 %)
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in group B (p =ns). The composite incidence of major
bleeding and clinically relevant non-major bleeding was
6.1 % (eight cases; 95 % CI, 2.9–12.1 %) in group A and
5.0 % (six cases; 95 % CI, 2.1–11.1 %) in group B (p =ns).
Conclusions A parnaparin dose of 4,250 IU/day seems
suitable for VTE prevention in patients undergoing bariatric
surgery.
Keywords Venous thromboembolism . Prophylaxis .
Parnaparin . Bariatric surgery . Obesity
Introduction
Recent studies have shown that venous thromboembolism
(VTE), including deep vein thrombosis (DVT) and pulmonary
embolism (PE), is a significant and frequent complication
after bariatric surgery [1–3]. Reported rates of post-operative
DVT and/or PE range from 1 to 15 % despite prophylaxis
[4–6], and about 50 % of deaths occurring in bariatric patients
are attributed to a fatal PE [7]. Therefore, prevention of VTE is
crucial in this clinical setting, and various regimens of low
molecular weight heparin (LMWH) are used for peri-
operative thromboprophylaxis [8–14]. However, there are no
clear guidelines regarding the optimal dosage of LMWH to
prevent VTE in morbidly obese patients [2, 15, 16]. For
example, Planes and colleagues have suggested that LMWHs
should be used prophylactically at a fixed dose, independently
of adjustments for body mass index (BMI) [17], while other
papers have shown better efficacy using a higher dose of the
drug in obese patients [8, 18]. Studies evaluating the weight-
based dosage of LMWH are limited, and criteria for dose
adjustment in obese (BMI >30 kg/m2) and severely obese
(BMI >50 kg/m2) patients remain controversial [19]. In
particular, given that the intravascular volume does not
have a linear relationship with body weight [20–22], it is
possible that the use of weight-based dosing in obese
patients could lead to overdosing; conversely, the use of a
fixed thromboprophylactic dose could result in underdosing,
while the safety and efficacy of a fixed intermediate dose have
not been adequately investigated.
We therefore performed a pilot, randomised, controlled,
open-label study evaluating efficacy and safety of a fixed
prophylactic dose of parnaparin (4,250 IU/day) with a fixed
intermediate dose of parnaparin (6,400 IU/day) in obese
patients undergoing bariatric surgery. Four thousand two
hundred fifty international units per day of parnaparin is the
recommended dose for the prevention of VTE in high-risk
general surgery [23], while 6,400 IU/day is slightly higher
than the 25 % increase in the standard prophylactic dose
suggested for severely obese patients at the consensus
conference of the American College of Chest Physicians
available when the study was planned [15].
Materials and Methods
Patient Population
Consecutive morbidly obese patients aged >18 years with a
BMI >36 kg/m2 who were scheduled to undergo open
and laparoscopic primary or revisional bariatric surgery
under general anaesthesia at six Italian centres were
eligible for inclusion. Exclusion criteria were as follows:
presence of liver disease (acute and chronic hepatitis,
cirrhosis, aminotransferases >3 times the normal upper
limit); kidney disease (creatinine levels >1.2 mg/dL);
platelet count <100,000/mm3; documented history of DVT/
PE in the last 6 months; documented congenital/acquired
coagulation disorders; concomitant anticoagulant/antiplatelet
therapy for other risk factors; known hypersensitivity to
heparin and derivatives; pregnancy; previous heparin-
induced thrombocytopenia; active peptic ulcer or known
angiodysplasia of the colon, severe uncontrolled hypertension
(systolic blood pressure ≥200 mmHg, diastolic ≥110 mmHg);
previous haemorrhagic stroke, recent brain surgery (<3months
from randomization), recent major bleeding (<3 months of
randomization), poor adherence to the study, withdrawal
of informed consent; and participation in another
clinical trial within the last 4 weeks or during the
current trial.
The study was approved by the local ethics committees and
written informed consent was obtained from all patients. The
study was conducted according to the European Guidelines
for Good Clinical Practice.
Study Design
BAFLUX is a prospective, randomised, open, pilot, controlled
multicentre national study. Randomisation was balanced for
sex and BMI (≤45 and >45 kg/m2). A centralised block-
balanced randomisation plan was used, stratified by centre,
gender and BMI. Eligible patients were randomised to
receive 4,250 IU/day (group A) or 6,400 IU/day (group B)
of subcutaneous parnaparin (Alfa Wassermann, Bologna,
Italy) starting 12 h preoperatively, the second dose 24 h later
and in any case at least 6 h after the closure of the surgical
wound, once adequate hemostasis has been achieved.
Subsequent injections were performed once a day for a
period of 9±2 days. Where the patient was discharged prior
to completion of the treatment, the treatment was completed
at home.
Patients were recommended to use graduated compression
stockings and intermittent pneumatic compression; early
deambulation was strongly encouraged.
Visit 1 was planned at the moment of patient recruitment,
visit 2 at the end of the drug administration period (day 9±2)
and visit 3 and visit 4 after 1 and 3 months of follow-up,
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respectively. A mandatory bilateral colour Doppler ultrasound
of the lower limb venous system was performed in each
patient before surgery and within 24 h of the end of the
treatment period (9±2 days).
At visits 1 and 2, the following blood chemistry exams
were performed: prothrombin time (PT), activated partial
thromboplastin time (aPTT), fibrinogen, creatinine,
aminotransferases, haemoglobin level, glucose levels, urine
output and platelet count. Pregnancy was excluded in fertile
women patients using the Gravindex test.
The primary efficacy endpoint was the combination of the
following VTE events occurring within 9 (±2)days: detection
of asymptomatic DVT by colour Doppler ultrasound
performed at the end of treatment (days 7–11), onset of
symptomatic DVT and/or symptomatic pulmonary embolism
(EP) (whether fatal or not) during the treatment period (with
instrumental confirmation) and death from any cause.
Secondary efficacy endpoints include each of the above
thrombotic events occurring individually: all DVTs, all
proximal DVTs, all isolated distal DVTs, non-fatal and fatal
PEs. In addition, symptomatic DVTs and PEs recorded during
the follow-up were secondary endpoints. The primary safety
endpoint was the combination of major bleeding and clinically
relevant non-major bleeding recorded between the first
administration of the drug until 2 days after the last injection.
Major bleeding is defined as fatal bleeding, bleeding in vital
organs (intracranial, intraspinal, retroperitoneal, intraarticular,
pericardial, intraocular); bleeding at the surgical site requiring
reoperation; and bleeding associated with a reduction in Hb of
at least 2 g/dL or requiring transfusion of at least 2 units of
packed red cells/whole blood. Bleeding was defined as
clinically relevant if it was overt but did not meet the other
criteria for major bleeding. Secondary safety endpoints are
the incidence of adverse events and thrombocytopenia.
Thrombocytopenia was defined as a 50 % reduction in
platelet count or less than 100,000 mm3. Heparin-induced
thrombocytopenia (HIT) was diagnosed according to the
combination of pre-test probability (4T score) and laboratory
tests showing anti-heparin-PF4 complex antibodies [24].
After inclusion in the BAFLUX Study, any sign or
symptom suggestive for VTE or bleeding during the treatment
period was reported. In case of clinical suspicion of DVT
or PE, an objective imaging testing was required to confirm
the diagnosis (for DVT: compressive ultrasonography,
colour Doppler ultrasound, computed tomography scan,
venography; for PE: perfusion lung scan matched with
chest X-ray, ventilation/perfusion scan, computed tomography,
angiography). In case of bleeding, blood count, PT, aPTT and
fibrinogen had to be performed, while any other diagnostic and
therapeutic measurements that the investigator considered
appropriate were recorded (e.g. radiology, endoscopy, etc.). A
central committee whose members were not involved in patient
recruitment and were unaware of any information regarding the
patients (i.e. study group assignments, risk factors for VTE or
bleeding) adjudicated the results of all suspected outcome
events on the basis of clinical reports or hospital discharge
letters sent in by the centres. In case of patient death, date and
cause were registered.
Ultrasound Examination
A 7.5–10-MHz linear ultrasound probe and a 3.5–5-MHz
convex probe were used. The examination was performed
with the patient in a supine position and horizontal dorsal
decubitus for the study of the femoral vein segments and in
a seated position for the study of the popliteal, tibial, fibular
and calf muscular vein segments. All venous segments of
the lower limbs, from the groin to the ankle, with colour
Doppler ultrasound and a compression manoeuvre were
evaluated. Detection of venous flow was performed using
spectral and coloured Doppler. The exam studied the
following venous segments: femoral, ramified segment of
the deep femoral, popliteal, posterior and anterior tibial,
fibular and calf muscular veins. The noncompressibility of
the vessel, the presence of hypoecogenic image, the
absence of spontaneous and phasic flow during breathing
and the nonincrease in flow during distal compression of
the studied vessel were all interpreted as positive signs of
lower limb DVT. The colour Doppler ultrasound test was
performed by clinicians blinded to the dose of parnaparin
given to the patients.
Statistical Analysis
Since this was a pilot study, no formal calculation of sample
size was performed. During this exploratory phase, it was
considered sufficient to enroll at least 100 patients per group
(200 patients in total). The demographic and clinical data were
summarised using frequency tables, or central tendency and
dispersion tables, using the most appropriate indicators for the
actual distribution of the individual variables (mean, standard
deviation, minimum and maximum values observed). In order
to evaluate the differences between groups, in the case of
nominal variables, the Pearson χ -squared test was applied,
while for continuous type variables, we used the t test for
independent samples when comparing groups and the t test for
dependent samples to analyse pre/post-treatment variations
within the same group; p values <0.05 were considered
significant. Statistical analysis was performed using the SPSS
Statistical Package, ver. 15.0 software.
Results
Between April 2004 and February 2012, 258 consecutive
morbidly obese patients (BMI >36) undergoing bariatric
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surgery were enrolled in this study. Eight subjects were not
evaluable for the safety analysis for the following reasons:
withdrawal of informed consent [1], refusing surgery [4]
and inclusion criteria not met [3]. Of the 250 evaluable
patients, 51 were males and 199 females with an age
ranging from 18 to 64, mean 40.9 SD ±9.7 years, with a
BMI range of 36.1–64.1 and mean 44.4 SD±5.4 kg/m2.
Baseline characteristics of the patients are reported in
Table 1, while risk factors for VTE and concomitant disease
are shown in Table 2; no statistically significant differences
were found between the two groups. After randomisation, 131
patients received 4,250 IU parnaparin/day (group A) and 119
patients received 6,400 IU parnaparin/day (group B); elastic
stockings were used in 224 patients (89.6 %), intermittent
pneumatic compression in 155 patients (62,0 %), early
deambulation in 241 patients (96.4 %) and electrical
stimulation in 3 patients (Table 3).
Bariatric procedures per treatment group are described
in Table 1. Preoperatively, no patients showed abnormal
ultrasound results at the colour Doppler ultrasound
examination.
During the treatment period, there were two (1.5 %; 95 %
confidence interval (CI), 0.2–6.0 %) VTE complications in
group A (that consisted of one non-fatal PE and one
asymptomatic distal DVT) and one VTE complication
(0.8 %; 95 % CI, 0.4–5.3 %) in group B (that consisted of
one symptomatic proximal DVT) (χ2 test, p =ns). No other
thrombotic complications occurred after hospital discharge
during the follow-up period. Eight patients in group A
(6.1 %; 95 % CI, 2.9–12.1 %) and six patients in group B
(5 %; 95 % CI, 2.1–11.1 %) showed major or clinically
relevant non-major bleeding (χ 2 test, p =ns). Major and
unusual bleeding occurred in 11/169 cases (6.5 %; 95 % CI
0.2–6.0 %) in gastric bypass-operated patients and in 3/81
cases (3.7 %) in other types of surgery (χ2 test, p =ns).
The number of cases of major and unusual bleeding
amounted to 7 (4.6 %) and 7 (7.3 %), respectively, in
patients with BMI ≤45 and >45 kg/m2 (test χ2, p =ns).
Table 4 shows the results of a multiple comparison test
between adverse events, type of surgery and treatment groups.
The small number of events does not allow multivariate
analysis.
No statistically significant differences were found between
the two groups regarding the incidence of adverse events
(Table 4); there was one case of thrombocytopenia in each
group, and there were no cases of HIT. During the treatment
and follow-up period, no patients died.
Discussion
The appropriate prophylactic dosage of anticoagulation for
VTE prevention in patients undergoing bariatric surgery is
still a matter of debate [2].
In this study, we compared the efficacy and safety of
two different fixed doses of parnaparin in a series of
258 bariatric patients. The results of our randomised,
pilot trial suggest that a standard prophylactic dose of
Table 1 Baseline characteristics of patients and bariatric procedures per treatment group
Group A Group B All patients p value
n=131 (%) n =119 (%) n =250 (%)
Sex
Female 106 (80.9) 93 (78.2) 199 (79.6) nsb
Male 25 (19.1) 26 (21.8) 51 (20.4)
Age (years)a 40.3±9.6 (18–64) 41.5±9.9 (18–63) 40.9±9.7 (18–64) nsc
Female 40.6±8.9 42.1±9.7 41.3±9.3
Male 39.3±12.0 39.2±10.4 39.3±11.1
BMI (kg/m2)a 44.6±5.4 (36.1–58.8) 44.2±5.4 (36.2–64.1) 44.4±5.4 (36.1–64.1) nsb
Surgery
Laparoscopic gastric bypass 85 (64.9) 84 (70.6) 169 (67.6)
Laparoscopic gastric banding 12 (9.2) 9 (7.6) 21 (8.4)
Biliopancreatic diversion 15 (11.5) 9 (7.6) 24 (9.6)
Vertical gastroplasty 1 (0.8) – 1 (0.4)
Laparoscopic sleeve gastrectomy 11 (8.4) 11 (9.2) 22 (8.8)
Other 7 (5.3) 6 (5.0) 13 (5.2)
Operating time (min, mean ± SD) 176±69 187±60 181±64 nsb
aMean ± SD (min–max)
bχ2 test
c t test for independent samples
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parnaparin (4,250 IU/day; group A) is as effective as a
higher intermediate dose (6,400 IU/day; group B), with
similar bleeding rates. During the treatment period, there
was an incidence of the primary efficacy endpoint
(composite of symptomatic and asymptomatic DVT, PE
and death from any case) of 1.5 % in group A as
compared with 0.8 % in group B (test χ 2, p =ns). The
primary safety outcome of major and clinically relevant
non-major bleeding was observed in 6.1 % of patients in
group A and in 5 % of patients in group B, respectively, the
rate of adverse events being similar in the two groups of
treatment. Our observations are consistent with those of
other trials evaluating the efficacy and safety of LMWH
in bariatric surgery, in which rates of VTE were 0.1 to
1.1 % and the corresponding rates of bleeding complications
were 1.8 to 5.9 % [8–11, 14, 18, 25]. The low incidence of
thrombotic events recorded in our study and the lack of
correlation with dose is presumably due to high rate of
patients receiving mechanical prophylaxis in addition to
pharmacological prophylaxis (89.6 % elastic stockings,
96.4 % early deambulation and 62 % intermittent pneumatic
compression, respectively).
Our results add interesting information about the optimal
anticoagulation dose for VTE prevention in bariatric surgery,
since very few studies have compared different doses of
heparin in this clinical setting. Scholten evaluated safety
and efficacy of two different doses of enoxaparin (30 mg
twice daily, group I; 40 mg twice daily, group II) in a
non-randomised study involving 481 patients undergoing
primary and revisional bariatric surgery [8]. There were a
total of 5.4 % VTE events in group I and 0.6 % in group
II, with a similar incidence of bleeding complications; in
conclusion, enoxaparin 40 mg twice daily reduced
thrombotic complications when compared with enoxaparin
30 mg, without an increase in hemorrhage risk.
Kalfarentzos randomised 60 consecutive patients
undergoing Roux-en-Y gastric bypass to receive either 5,
700 or 9,500 IU of nadroparin [9]. The lower dose did
not increase the risk of post-operative thrombotic disease,
while coagulation parameters were similar with both doses
in all post-operative analyses, including the 3- and 6-
month follow-up. Importantly, there were no bleeding
events in the 5,700-IU group compared with two with
the higher dose, suggesting that the lower dose should
be considered for the prophylaxis of VTE in bariatric
surgical patients. In a prospective open trial, 223 patients
undergoing Roux-en-Y gastric bypass were assigned to
receive enoxaparin 40 mg (BMI ≤50 kg/m2; n =124) or
Table 2 VTE risk factors and
concomitant pathology
The two groups are not
significantly different in terms
of frequency of risk factors and
incidence of comorbidities
(χ2 test, T=ns)
Group A Group B All patients
(n =250)Parnaparin Parnaparin
4,250 IU (n=131) 6,400 IU (n =119)
Varicose veins, surgery for varicose veins 7 (5.3 %) 12 (10.1 %) 19 (7.6 %)
Previous deep vein thrombosis 1 – 1 (0.4 %)
Previous pulmonary embolism – – –
Major surgery in last 3 months – – –
Previous immobilisation >7 days in the
last month
– – –
Previous myocardial infarction 1 1 2 (0.8 %)
Previous stroke 1 – 1 (0.4 %)
Smoking 29 (22.1 %) 32 (26.9 %) 61 (24.4 %)
Heart failure – 4 (3.4 %) 4 (1.6 %)
Respiratory failure 10 (7.6 %) 16 (13.4 %) 26 (10.4 %)
Paralysis – – –
Progestin replacement or contraceptive therapy 10 (7.6 %) 7 (5.9 %) 17 (6.8 %)
Other risk factors 6 (4.6 %) 2 (17 %) 8 (3.2 %)
Diabetes mellitus 14 (10.7 %) 20 (16.8 %) 34 (13.6 %)
Arterial hypertension 48 (36.6 %) 44 (37.0 %) 92 (36.8 %)
Ischemic cardiomyopathy 2 (1.5 %) 2 (1.7 %) 4 (1.6 %)
Rheumatic diseases 27 (20.6 %) 32 (26.9 %) 59 (23.6 %)
Chronic obstructive pulmonary disease 16 (12.2 %) 20 (16.8 %) 36 (14.4 %)
Peripheral arterial disease – 3 (2.5 %) 3 (1.2 %)
Chronic liver disease 2 (1.5 %) 6 (5.0 %) 8 (3.2 %)
Renal failure 2 (1.5 %) 1 (0.8 %) 3 (1.2 %)
Other diseases 5 (3.8 %) 8 (6.7 %) 13 (5.2 %)
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60 mg (BMI>50 kg/m2, n =99) every 12 h during
hospitalisation and once daily for 10 days after discharge
[18]. The anti-Xa levels were monitored serially, and dose
adjustments were made for results outside the target
prophylactic range (0.2–0.4 IU/mL) after the third dose.
One patient developed non-fatal VTE (0.45 %) and four
patients required transfusion for major bleeding (1.79 %).
Our results are also consistent with those reported in
three recently published studies on the pharmacodynamic
activity of LMWHs in bariatric patients [26–28]. In a
study of 66 patients undergoing surgery for severe obesity,
Imberti and colleagues showed that a fixed prophylactic
dose of parnaparin (4,250 IU/day) was able to achieve
prophylactic anti-Xa levels in 98.3 % of patients, while
a higher dosage (6,400 IU/day) was associated with
excessive anti-Xa levels in 62.3 % of patients [26].
Forestieri and co-workers demonstrated in a small series
of ten severely obese patients (BMI >50 kg/m2) that doses
of both 4,250 and 6,400 IU/day of parnaparin may
provide effective prophylaxis for VTE in the peri-
operative period; the authors speculated that higher doses,
which may be associated with higher rates of bleeding
complications, would offer no real improvement in
efficacy [27]. In the non-randomised study by Simone
and colleagues, patients undergoing laparoscopic bariatric
surgery received enoxaparin 40 or 60 mg every 12 h [28].
No supratherapeutic anti-Xa concentrations were observed
in the 40-mg group, whereas 57 % of the third dose levels
in the 60-mg group were supratherapeutic.
Our results indicate that the standard prophylactic dose
of parnaparin may be sufficient for VTE prevention in
bariatric surgery, suggesting that higher doses are not
necessary in this clinical setting. This finding is in
agreement with the results of two studies assessing
therapeutic doses of dalteparin [29] and a prophylactic
dose of nadroparin [30] or enoxaparin [31] in obese
patients and is in contrast with the results of other studies
[8, 32] that suggested the need to adjust the dosage of
LMWH according to body weight.
This study has some limitations. First, because of the small
sample size, the results of our trial must be interpreted with
caution; any conclusions cannot be definitively drawn and are
only hypothesis generating. However, this is, to our
knowledge, the largest randomised clinical study comparing
two different dosages of LMWH in bariatric surgery ever
published; moreover, the practical difficulties associated with
obtaining suitable patients in this clinical setting make our
Table 4 Incidence of bleeding and adverse events






Major or clinical relevant
bleeding
8/131 (6.1 %) 6/119 (5 %) 14/250 (5.6 %)
Gastric bypass 7/85 (8.2 %) 4/84 (4.8 %) 11/169 (6.5 %)
Other surgery 1/46 (2.2 %) 2/35 (5.7 %) 3/81 (3.7 %)
Transfusions (patients) 4 3 7
No. of units of blood
Intra-op., 1 unit 1 – 1
No. of units of blood
Post-op., 1 unit 1 2 3
2 units 2 1 3
3 units – – –
4 units 1 – 1
Thrombocytopenia 1 1 2
Table 3 Type and duration of
prophylaxis
a t test for independent samples = ns
bχ2 test=ns
Group A Group B All patients
(n =250)Parnaparin Parnaparin
4,250 IU (n =131) 6,400 IU (n =119)
Total duration of prophylaxis with low
molecular weight heparin (in days)a
14.1±2.4 (1–15) 14.0±2.5 (2–15) 14.1±2.4 (1–15)
Muscle electrostimulation during surgeryb 1 2 3
Intermittent pneumatic compression (IPC)b 79 (60.3 %) 76 (63.9 %) 155 (62.0 %)
Elastic stockings (ES)b 116 (88.5 %) 108 (90.8 %) 224 (89.6 %)
Early deambulation (ED)b 126 (96.2 %) 115 (96.6 %) 241 (96.4 %)
Heparin alone 2 (1.5 %) 2 (1.7 %) 4 (1.6 %)
Heparin + IPC – – –
Heparin + ES 3 (2.3 %) 2 (1.7 %) 5 (2.0 %)
Heparin + ED 10 (7.6 %) 6 (5.0 %) 16 (6.4 %)
Heparin + IPC +ED 3 (2.3 %) 3 (2.5 %) 6 (2.4 %)
Heparin + ES +ED 37 (28.2 %) 32 (26.9 %) 69 (27.6 %)
Heparin + IPC +ES + ED 76 (58.0 %) 74 (62.2 %) 150 (60.0 %)
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results, albeit limited and preliminary, of interest. Moreover, a
non-inferiority large-scale clinical trial seems not easily
feasible because of the very large sample size; using the results
of our pilot study and considering VTE events (with an event
rate in the two groups of 1.5 % and non-inferiority margin of
0.7 %) as the primary efficacy outcomes, the calculated
sample size is 3,729 patients for group (alpha=0.05 and
80 % power), and if we considered as primary outcome the
composite incidence of major bleeding and clinically relevant
non-major bleeding (with event rate of 6.1 %, non-inferiority
margin of 1.1 %, alpha=0.05 and 80 % power), the sample
size is even higher (5,754 patients for group). Second,
since our study has an open design, there are potential
randomisation and diagnostic bias. In order to reduce this
possibility, a centralised block-balanced randomisation plan
was used, stratified by centre, gender and BMI. Moreover,
the colour Doppler ultrasound test was performed by
clinicians blinded to the dose of parnaparin given to the
patients and all the suspected outcome events were
adjudicated by a central committee whose members were
unaware of any information regarding the patients. Third,
the use of colour Doppler ultrasound for the detection of
asymptomatic DVT in obese patients is questionable, since
given its low sensitivity [33, 34]. On the other hand, a
phlebographic study was not feasible and every effort was
used when examining each patient, such as compression
manoeuvre and coloured and spectral Doppler, to improve
the accuracy of the exams as much as possible, and these
were repeated where necessary. Fourth, the duration of the
study was quite long because recruitment was slower than
anticipated in three centres and was stopped in the other
three centres as a result of expiration of the study drug.
In conclusion, our pilot study suggests that a dose of 4,
250 IU/day of parnaparin seems adequate to prevent VTE
complications in patients undergoing surgery for morbid
obesity. Definitive validation for the daily clinical practice of
4,250 IU/day of parnaparin for VTE prophylaxis in bariatric
surgery now should be theoretically confirmed in large
randomised controlled trials, even if these studies are not
easily feasible (and probably even unfeasible) due to the very
large sample size.
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– De Paoli Marco, Chirurgia Generale, Ospedale Galliera, Genova (23
patients)
– Mariani Enrico, Boni Marcello, Chirurgia Generale, Flamini
Flaminio Otello, Filippucci Esmeralda U.O. Angiologia, Ospedale
San Giovanni Battista, Foligno (Perugia) (14 patients)
– Amenta Enrico, Cariani Stefano, Guerra Manuela, Centro Studi
Obesità Patologica, Chirurgia Generale III, Policlinico Sant’Orsola
Malpighi, Bologna (12 patients)
– Bottani Giorgio, Zanardi Alberto, Ospedale Civile, Dipartimento di
Chirurgia Generale, Mortara (Pavia) (11 patients)
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